首页> 外文期刊>Biochimica et biophysica acta. Molecular cell research >Cathepsin D-like aspartyl protease activity mediates the degradation of tissue-type plasminogen activator/plasminogen activator inhibitor-1 complexes in human monocytes
【24h】

Cathepsin D-like aspartyl protease activity mediates the degradation of tissue-type plasminogen activator/plasminogen activator inhibitor-1 complexes in human monocytes

机译:组织蛋白酶D样天冬氨酰蛋白酶活性介导人单核细胞中组织型纤溶酶原激活物/纤溶酶原激活物抑制剂-1复合物的降解

获取原文
获取原文并翻译 | 示例
           

摘要

Plasminogen activator inhibitor-1 (PAI-1) is the most important inhibitor of tissue-type plasminogen activator (t-PA) in plasma and plays a major role in the regulation of fibrinolysis. Plasma t-PA/PAI-1 complexes are cleared via a receptor-dependent mechanism in hepatocytes, while the fate of complexes formed in the extracellular matrix and in thrombi is less well understood. In this study, the degradation of t-PA/PAI-1 complexes by monocytes was examined. THP-1 monocytoid cells and freshly isolated human monocytes internalize and degrade [125I]t-PA/PAI-1 complexes at rates of 11.4 ± 5.9 (mean ± S.D.) and 44.6 ± 6.3 ng/106 cells/h, respectively. Degradation is blocked by receptor-associated protein (RAP), indicating a member of the low density lipoprotein (LDL) receptor family is involved in the uptake /degradation of t-PA/PAI-1 complexes by monocytes. Degradation of t-PA/PAI-1 complexes is also inhibited by chloroquine and by pepstatin A, suggesting that a lysosomal aspartyl protease is likely involved. SDS-PAGE and Western blotting demonstrated that the purifed. lysosomal aspartyl protease, cathepsin D, is capable of digesting t-PA (t1/2 15 min), active PAI-1 (t1/2 2 h), and t-PA/PAI-1 complex (t1/2 30 min). Cathepsin D sequentially cleaves PAI-1 after hydrophobic amino acids, yielding lower molecular weight fragments. PAI-1 conformation influences the degradative efficiency of cathepsin D, with vitronectin-bound PAI-1 and latent PAM exhibiting resistance to proteolysis and > 10-fold prolongation in t1/2. These data provide evidence that t-PA/PAI-1 complexes are internalized by human monocytes via a member of the low density lipoprotein (LDL) receptor family, and identifies cathepsin D-like aspartyl protease activity as largely responsible for the degradation of these complexes. Furthermore, vitronectin-bound PAM and latent PAI-1 are relatively resistant to degradation by cathepsin D, which may be of importance in complex physiological environments.
机译:纤溶酶原激活物抑制剂1(PAI-1)是血浆中组织型纤溶酶原激活物(t-PA)的最重要抑制剂,在纤维蛋白溶解的调节中起主要作用。血浆t-PA / PAI-1复合物通过受体依赖性机制在肝细胞中清除,而在细胞外基质和血栓中形成的复合物的命运还不太清楚。在这项研究中,检查了单核细胞对t-PA / PAI-1复合物的降解。 THP-1单核细胞和新鲜分离的人单核细胞分别以11.4±5.9(平均±标准差)和44.6±6.3 ng / 106细胞/ h的速率内化和降解[125I] t-PA / PAI-1复合物。降解被受体相关蛋白(RAP)阻断,表明低密度脂蛋白(LDL)受体家族的一员参与了单核细胞对t-PA / PAI-1复合物的摄取/降解。 t-PA / PAI-1复合物的降解也受到氯喹和胃蛋白酶抑制素A的抑制,表明溶酶体天冬氨酰蛋白酶可能参与其中。 SDS-PAGE和Western blotting证明已纯化。溶酶体天冬氨酰蛋白酶组织蛋白酶D能够消化t-PA(t1 / 2 15分钟),活性PAI-1(t1 / 2 2 h)和t-PA / PAI-1复合物(t1 / 2 30分钟) 。组织蛋白酶D在疏水性氨基酸之后顺序切割PAI-1,产生较低分子量的片段。 PAI-1构象影响组织蛋白酶D的降解效率,玻连蛋白结合的PAI-1和潜伏的PAM表现出对蛋白水解的抗性和t1 / 2延长> 10倍。这些数据提供了证据,表明t-PA / PAI-1复合物被人单核细胞通过低密度脂蛋白(LDL)受体家族的成员内在化,并确定组织蛋白酶D样天冬氨酰蛋白酶活性是造成这些复合物降解的主要原因。此外,结合玻连蛋白的PAM和潜在PAI-1对组织蛋白酶D的降解具有相对的抵抗力,这在复杂的生理环境中可能很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号